The Oligonucleotide Synthesis, Modification, and Purification Services Market Size is valued at USD 4.3 billion in 2023 and is predicted to reach USD 9.15 billion by the year 2031 at a 10.06 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The increasing focus on understanding genetic mechanisms and developing new therapies drives demand for oligonucleotide synthesis and related services.
- Companies investing in innovative synthesis platforms and purification techniques can capture a larger market share.
- North America dominated the market and accounted for a global revenue share in 2023.
- The cost of oligonucleotide synthesis can be significant, especially for custom or modified sequences. This expense may limit adoption, particularly for smaller research labs or organizations with limited budgets.
Synthetic DNA oligonucleotides are applied in a wide range of applications, from fundamental research to clinical diagnostics and biotherapeutics. Oligonucleotides are chemically synthesized molecular chains from nucleosides. Solid-phase synthesis is the most popular method used for oligonucleotides chemical synthesis. They have a variety of uses in biology, biochemistry, molecular diagnostics, genomics, forensics, and others. Selecting the suitable oligonucleotide synthesizer for application is critical to optimizing product quality while maintaining cost-effectiveness.
The primary elements boosting the growth of the oligonucleotide synthesis, modification, and purification services market include increasing demand for oligonucleotides, growing preference of patients toward personalized medicines, rising collaborations and mergers/acquisitions by manufacturers, and growing older population, and the high prevalence of chronic diseases. Apart from this, the need for high-quality oligos is increasing due to the increase in R&D activities. Therefore, biotech and pharmaceutical companies' increasing research and development activities to treat various viral infections, chronic diseases, and genetic disorders are expected to fuel market growth over the forecast years.
For instance, in July 2017, Nitto Denko Avecia Inc. (Avecia) opened a new oligonucleotide API manufacturing facility in Milford, MA. The expansion has added 20,000 sq. ft. of manufacturing and office space at the site and provided CGMP oligonucleotide manufacturing capacity up to 1.8 mol, bringing the site capacity to 3.0 mol. Also, this expansion has helped Avecia's clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials. However, the low-quality oligonucleotide sequences, lack of technical requirements, and the complexities associated with the oligonucleotide synthesis may hamper the market growth.
Competitive Landscape
Some Of The Key Players In The Oligonucleotide Synthesis, Modification, and Purification Services Market:
- Agilent Technologies
- Ajinomoto Bio-Pharma Services
- CordenPharma
- Integrated DNA Technologies
- Kaneka Eurogentec
- LGC Biosearch Technologies
- Microsynth
- Merck
- Nitto Avecia
- Thermo Fisher Scientific
- TriLink BioTechnologies
- Creative Biolabs
- Ella Biotech
- Eurofins Genomics
- Future Synthesis
- Ribo Biotechnology
- STA Pharmaceutical
- GE Healthcare
- GeneDesign, Inc.
- Bio-synthesis Inc.
- Almac Group
- Sumitomo Chemical
- Axolabs (LGC Group)
- MilliporeSigma
- BioSpring
- ChemGenes
- BianoScience GmbH
- ATDBio Ltd
- Burkert UK Limited
- IBA Lifesciences GmbH
Market Segmentation
The Oligonucleotide Synthesis, Modification, and Purification Services Market is segmented into application area, type of product synthesized, type of oligonucleotide synthesized, scale of operation, therapeutic area, end-users, and company size. Based on application area research and diagnostics, and therapeutics, the market is segmented into research and diagnostics, and therapeutics. Based on the type of product synthesized, the market is segmented into active pharmaceutical ingredients and finished dosage forms. Based on the type of oligonucleotide synthesized, the market is segmented into antisense, DNA, SIRNA, and other oligonucleotides. Based on the scale of operation the market is segmented into clinical and commercial. Based on the therapeutic area the market is segmented into cardiovascular disorders, genetic disorders, liver disorders, rare diseases, and other disorders. Based on the end-users, the market is segmented into pharmaceutical/biopharmaceutical companies, academic and research institutes, and hospitals. Based on the Company size, the market is segmented into small, mid-sized, and large and very large.
The market is being examined throughout North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Due to increased R&D investments in pharma and biotech businesses to enhance oligonucleotide production and synthesis processes, North America is likely to have the largest share of this market throughout the forecast years, followed by Europe.
Recent Developments:
- In October 2023, Integrated DNA Technologies established a new production facility for therapeutic oligonucleotides in Iowa, USA. Customers will benefit from expanded research and manufacturing capabilities and knowledge provided by the 41,000 square foot facility.
The Oligonucleotide Synthesis, Modification, and Purification Services Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 4.3 Bn |
|
Revenue Forecast In 2031 |
USD 9.15 Bn |
|
Growth Rate CAGR |
CAGR of 10.06 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Application Area, Type of Product Synthesized, Type of Oligonucleotide Synthesized, Scale of Operation, Therapeutic Area, End-Users, And Company Size |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Ajinomoto Bio-Pharma Services, Integrated DNA Technologies, Kaneka Eurogentec, LGC Biosearch Technologies, Microsynth, MilliporeSigma, BioSpring, CordenPharma, Nitto Denko Avecia, TriLink Biotechnologies, Eurofins Scientific SE, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., GE Healthcare, GeneDesign, Inc., Bio-synthesis Inc., ATDBio Ltd, Burkert UK Limited, Almac Group, and Other Prominent Players |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
